Travere Therapeutics (TVTX) Financial Statements & Analysis

Travere Therapeutics (TVTX) Income Statement

Travere Therapeutics reported revenue of $490.73M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 110.5% from $233.18M a year earlier. Travere Therapeutics posted a net loss of $25.55M, compared with a net loss of $321.55M a year earlier. Gross margin was 97.9% and operating margin -12.8%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $169.58M, up 48.2% from the same quarter a year earlier.

Travere Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Travere Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	490.73	233.18	145.24	109.46	131.84	198.32	175.34	164.25	154.94
Cost of Revenue	10.34	7.74	11.45	4.42	3.82	6.13	5.23	5.53	3.61
Gross Profit	480.39	225.43	133.79	105.04	128.02	192.20	170.10	158.72	151.33
Operating Expenses
Research & Development	206.01	282.70	244.99	227.33	201.16	131.77	140.96	123.76	78.17
Selling, General & Administrative	337.20	264.12	265.54	197.52	126.28	135.80	128.95	103.65	103.96
Operating Expenses	543.21	549.26	521.93	424.85	327.44	368.36	269.91	227.41	182.13
Operating Income	-62.82	-323.83	-388.14	-319.81	-199.43	-176.16	-99.81	-80.04	-53.79
Other Income/Expense
Interest Income	12.72	17.82	21.77	6.28	1.99	5.00	10.06	5.50	3.23
Interest Expense	10.75	11.18	11.33	11.01	19.68	19.05	18.83	9.81	4.42
Other Income/Expense	11.58	3.32	12.03	-6.60	0.23	-12.63	-46.64	-21.83	-30.19
Income
Income Before Tax	-49.27	-320.51	-376.11	-331.16	-216.88	-188.79	-146.45	-101.87	-58.36
Income Tax Expense	0.99	0.12	0.22	0.31	0.41	-19.36	-0.02	0.81	1.37
Net Income	-25.55	-321.55	-111.40	-278.48	-180.09	-169.43	-146.43	-102.68	-59.73
Net Income - Continuous Operations	-50.26	-321.55	-111.40	-331.47	-217.29	-169.43	-146.43	-102.68	-59.73
Net Income - Discontinued Operations	24.72	-0.92	264.93	52.99	37.20	-	-	-	-
EBITDA	22.22	-265.77	-326.25	-299.42	-184.46	-145.16	-107.21	-73.39	-38.67
EBIT	-38.53	-256.18	-364.78	-320.14	-197.20	-	-	-	-
Depreciation & Amortization	60.74	43.56	38.53	20.72	12.75	24.58	20.41	18.67	17.80
Earnings Per Share
Basic EPS	-	-4.00	-1.00	-4.00	-3.00	-4.00	-3.00	-3.00	-2.00
Diluted EPS	-	-4.00	-1.00	-4.00	-3.00	-4.00	-3.00	-3.00	-2.00
Basic Shares Outstanding	89.21	78.89	74.27	63.76	59.83	47.54	42.34	40.42	38.77
Diluted Shares Outstanding	89.21	78.89	74.27	63.76	59.83	47.54	42.34	40.43	38.77

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Travere Therapeutics Financial Statements

What was Travere Therapeutics's revenue in fiscal 2025?

Travere Therapeutics reported revenue of $490.73M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 110.5% from $233.18M a year earlier.

Is Travere Therapeutics profitable?

No. Travere Therapeutics reported a net loss of $25.55M in fiscal 2025. In fiscal 2024 it lost $321.55M.

What is Travere Therapeutics's operating margin?

Travere Therapeutics's operating income was −$62.82M on revenue of $490.73M in fiscal 2025, an operating margin of -12.8%, compared with -138.9% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition